Mortality trends for cervical squamous and adenocarcinoma in the United States

In the United States, detection of squamous carcinoma in situ (CIS) by screening has led to reduced rates for invasive squamous carcinoma and lower mortality. Adenocarcinoma in situ (AIS) rates also have increased, but invasive cervical adenocarcinoma rates have not declined similarly. To make inferences about the effectiveness of screening, the authors assessed mortality trends for squamous and adenocarcinoma in relation to incidence of these tumors, incidence of their precursors and survival.

[1]  M. Quinn,et al.  Microinvasive Adenocarcinoma of the Cervix: A Clinicopathologic Study of 77 Women , 1997, Obstetrics and gynecology.

[2]  S. Granter,et al.  Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix. A study of 34 cases. , 1997, American journal of clinical pathology.

[3]  David R. Scott,et al.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. , 2003, Journal of the National Cancer Institute.

[4]  H. Sung,et al.  Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. , 2003, Obstetrics and gynecology.

[5]  S. Granter,et al.  Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix , 2001, Cancer.

[6]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[7]  C. Wheeler,et al.  Risk factors for rapid-onset cervical cancer. , 1999, American journal of obstetrics and gynecology.

[8]  P. Porter,et al.  Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  C. Woodman,et al.  Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.

[10]  M. Saville,et al.  Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening , 2003, Cancer.

[11]  S. Saltzstein,et al.  Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. , 1999, Gynecologic oncology.

[12]  T. Reynolds.  States begin CDC-sponsored breast and cervical cancer screening. , 1992, Journal of the National Cancer Institute.

[13]  E. Feuer,et al.  A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. , 1994, Journal of clinical epidemiology.

[14]  G. Chêne,et al.  Survival and prognosis of women with invasive cervical cancer according to age. , 2003, Gynecologic oncology.

[15]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[16]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[17]  P. Boyle,et al.  The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. , 1996, International journal of epidemiology.

[18]  M. Schiffman,et al.  Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. , 2003, Journal of the National Cancer Institute. Monographs.

[19]  V. Václavinková.  Behavior of Moderate Cervical Dysplasia During Long-Term Follow-Up , 1983, Obstetrics and gynecology.

[20]  J. Fiorica.  The role of topotecan in the treatment of advanced cervical cancer. , 2003, Gynecologic oncology.

[21]  M. Sherman,et al.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000 , 2004, Cancer.

[22]  G. Giles,et al.  Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. , 1995, British Journal of Cancer.

[23]  M. Sherman,et al.  Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  V. Moreno,et al.  International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas , 1998, International journal of cancer.

[25]  G. Friedell,et al.  Adenocarcinoma in situ of the endocervix , 1953, Cancer.

[26]  C. Key,et al.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.

[27]  Evan R. Myers,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .

[28]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[29]  Diane Solomon,et al.  The Bethesda System for Reporting Cervical Cytology , 2004 .

[30]  H. 0. Smith,et al.  Adenocarcinoma in situ of the cervix: Sensitivity of detection by cervical smear , 2002, Cancer.

[31]  L. Becker,et al.  Are fluid-based cytologies superior to the conventional Papanicolaou test? A systematic review. , 2001, The Journal of family practice.

[32]  A. Raffle,et al.  Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented , 2003, BMJ : British Medical Journal.